Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA appropriations

This article was originally published in The Tan Sheet

Executive Summary

CFSAN Adverse Events Reporting System would receive $7.6 mil. in FY 2003 funding - including $1.5 mil. for dietary supplements - under Senate Ag Approps bill, which unanimously passed out of committee July 25. CAERS funding represents $2 mil. more than budget request. Measure also provides $2 mil. for botanical research carried out by FDA, U-Miss. center. Generic drugs program would receive $45.3 mil. in funding, a $6.1 mil. increase over FY 2002 level and $1.5 mil. above budget request. Bill calls for $179.2 mil. in funding for CDER, $149.3 mil. for CFSAN and total FDA funding of $1.39 bil., which is $23.4 mil. more than budget request. Full Senate vote has yet to be scheduled...
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS094325

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel